{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T08:40:14Z","timestamp":1789980014152,"version":"4.0.1"},"reference-count":188,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.rdc.2018.06.006","type":"journal-article","created":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T04:56:28Z","timestamp":1536296188000},"page":"675-698","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Autoimmune Kidney Diseases Associated with Chronic Viral Infections"],"prefix":"10.1016","volume":"44","author":[{"given":"Joshua D.","family":"Long","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie M.","family":"Rutledge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan E.","family":"Sise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"37","key":"10.1016\/j.rdc.2018.06.006_bib1","doi-asserted-by":"crossref","first-page":"13293","DOI":"10.3748\/wjg.v20.i37.13293","article-title":"Update on hepatitis B virus infection","volume":"20","author":"You","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"5 Suppl","key":"10.1016\/j.rdc.2018.06.006_bib2","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1002\/hep.22881","article-title":"Hepatitis B: the virus and disease","volume":"49","author":"Liang","year":"2009","journal-title":"Hepatology"},{"issue":"18","key":"10.1016\/j.rdc.2018.06.006_bib3","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.3748\/wjg.v20.i18.5427","article-title":"Hepatitis B virus genotypes: global distribution and clinical importance","volume":"20","author":"Sunbul","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.rdc.2018.06.006_bib4","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1111\/j.1523-1755.2005.00591.x","article-title":"Lamivudine in hepatitis B-associated membranous nephropathy","volume":"68","author":"Tang","year":"2005","journal-title":"Kidney Int"},{"issue":"7718","key":"10.1016\/j.rdc.2018.06.006_bib5","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0140-6736(71)92572-4","article-title":"Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane","volume":"2","author":"Combes","year":"1971","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.rdc.2018.06.006_bib6","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJM199105233242103","article-title":"Membranous nephropathy related to hepatitis B virus in adults","volume":"324","author":"Lai","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.006_bib7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11901-010-0042-6","article-title":"Hepatitis B and renal disease","volume":"9","author":"Chan","year":"2010","journal-title":"Curr Hepat Rep"},{"issue":"6","key":"10.1016\/j.rdc.2018.06.006_bib8","doi-asserted-by":"crossref","first-page":"456","DOI":"10.5414\/CN107615","article-title":"Clinical and pathological analysis of hepatitis B virus-related membranous nephropathy and idiopathic membranous nephropathy","volume":"78","author":"Li","year":"2012","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.rdc.2018.06.006_bib9","series-title":"Recent advances in pediatric nephrology","article-title":"Hepatitis B virus-associated glomerulonephritis in children","author":"Takekoshi","year":"1987"},{"issue":"15","key":"10.1016\/j.rdc.2018.06.006_bib10","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1056\/NEJM197904123001502","article-title":"Free \"small\" and IgG-associated \"large\" hepatitis B e antigen in the serum and glomerular capillary walls of two patients with membranous glomerulonephritis","volume":"300","author":"Takekoshi","year":"1979","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.006_bib11","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/ki.1984.178","article-title":"Deposition of hepatitis B e antigen in membranous glomerulonephritis: identification by F(ab')2 fragments of monoclonal antibody","volume":"26","author":"Hirose","year":"1984","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.006_bib12","first-page":"109","article-title":"The role of hepatitis B surface antigen in the pathogenesis of glomerulopathies","volume":"12","author":"Nagy","year":"1979","journal-title":"Clin Nephrol"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.006_bib13","first-page":"619","article-title":"Immune complexes of hepatitis B surface antigen in the pathogenesis of periarteritis nodosa. A study of seven necropsy cases","volume":"90","author":"Michalak","year":"1978","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.006_bib14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000184477","article-title":"IgA nephropathy associated with hepatitis B virus antigenemia","volume":"47","author":"Lai","year":"1987","journal-title":"Nephron"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.006_bib15","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000169083","article-title":"Treatment of hepatitis B virus associated glomerulonephritis with recombinant human alpha interferon","volume":"17","author":"Chung","year":"1997","journal-title":"Am J Nephrol"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.006_bib16","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ki.1990.32","article-title":"Hepatitis B infection and renal disease: clinical, immunopathogenetic and therapeutic considerations","volume":"37","author":"Johnson","year":"1990","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.006_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ki.1980.1","article-title":"In situ immune complex formation and glomerular injury","volume":"17","author":"Couser","year":"1980","journal-title":"Kidney Int"},{"key":"10.1016\/j.rdc.2018.06.006_bib18","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1146\/annurev.me.39.020188.002505","article-title":"Pathogenesis of membranous nephropathy","volume":"39","author":"Couser","year":"1988","journal-title":"Annu Rev Med"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.006_bib19","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000185053","article-title":"Biochemical and serological characteristics of children with membranous nephropathy due to hepatitis B virus infection: correlation with hepatitis B e antigen, hepatitis B DNA and hepatitis D","volume":"49","author":"Milner","year":"1988","journal-title":"Nephron"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.006_bib20","first-page":"214","article-title":"Hepatitis B e antigen-mediated membranous glomerulonephritis. Correlation of ultrastructural changes with HBeAg in the serum and glomeruli","volume":"44","author":"Ito","year":"1981","journal-title":"Lab Invest"},{"issue":"4","key":"10.1016\/j.rdc.2018.06.006_bib21","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/j.1572-0241.2005.41308.x","article-title":"Hepatitis B virus replication in damaged endothelial tissues of patients with extrahepatic disease","volume":"100","author":"Mason","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"4\u20135","key":"10.1016\/j.rdc.2018.06.006_bib22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000431331","article-title":"Renal phospholipase A2 receptor in hepatitis B virus-associated membranous nephropathy","volume":"41","author":"Xie","year":"2015","journal-title":"Am J Nephrol"},{"issue":"5","key":"10.1016\/j.rdc.2018.06.006_bib23","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/hep.1840060525","article-title":"Evidence for a deficiency of interferon production in patients with chronic hepatitis B virus infection acquired in adult life","volume":"6","author":"Ikeda","year":"1986","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.006_bib24","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000077065","article-title":"Hepatitis B virus-associated nephropathy","volume":"24","author":"Bhimma","year":"2004","journal-title":"Am J Nephrol"},{"issue":"6","key":"10.1016\/j.rdc.2018.06.006_bib25","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00467-001-0814-x","article-title":"Treatment of hepatitis B virus-associated nephropathy in black children","volume":"17","author":"Bhimma","year":"2002","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.006_bib26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1399-0039.1998.tb02276.x","article-title":"HLA-DRB and -DQB1 alleles in Polish patients with hepatitis B associated membranous nephropathy","volume":"52","author":"Vaughan","year":"1998","journal-title":"Tissue Antigens"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.006_bib27","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5414\/CNP70069","article-title":"Long-term (7-year-) treatment with lamivudine monotherapy in HBV-associated glomerulonephritis","volume":"70","author":"Mesquita","year":"2008","journal-title":"Clin Nephrol"},{"issue":"4","key":"10.1016\/j.rdc.2018.06.006_bib28","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3904\/kjim.2012.27.4.394","article-title":"Treatment of hepatitis B virus-associated membranous nephropathy: lamivudine era versus post-lamivudine era","volume":"27","author":"Moon","year":"2012","journal-title":"Korean J Intern Med"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.006_bib29","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/0016-5085(95)90343-7","article-title":"Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa","volume":"109","author":"Conjeevaram","year":"1995","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.006_bib30","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/ki.1995.27","article-title":"Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon","volume":"47","author":"Lin","year":"1995","journal-title":"Kidney Int"},{"issue":"10","key":"10.1016\/j.rdc.2018.06.006_bib31","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1155\/2005\/378587","article-title":"Lamivudine for the treatment of membranous glomerulopathy secondary to chronic Hepatitis B infection","volume":"19","author":"Gan","year":"2005","journal-title":"Can J Gastroenterol"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.006_bib32","first-page":"101","article-title":"Hepatitis B virus-associated nephropathy: an International Data Analysis","volume":"4","author":"Khedmat","year":"2010","journal-title":"Iran J Kidney Dis"},{"issue":"5","key":"10.1016\/j.rdc.2018.06.006_bib33","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/j.1365-2036.2006.03041.x","article-title":"Meta-analysis: anti-viral therapy of hepatitis B virus-associated glomerulonephritis","volume":"24","author":"Fabrizi","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.rdc.2018.06.006_bib34","first-page":"175","article-title":"Antiviral treatment for chronic hepatitis B virus infection\u2013immune modulation or viral suppression?","volume":"64","author":"Buster","year":"2006","journal-title":"Neth J Med"},{"issue":"7","key":"10.1016\/j.rdc.2018.06.006_bib35","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/gast.2001.24839","article-title":"Management of hepatitis B: 2000\u2013summary of a workshop","volume":"120","author":"Lok","year":"2001","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.rdc.2018.06.006_bib36","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A\u00a0comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B","volume":"354","author":"Chang","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.006_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1872-034X.2010.00739.x","article-title":"Management of hepatitis B: consensus of the Japan Society of Hepatology 2009","volume":"41","author":"Yokosuka","year":"2011","journal-title":"Hepatol Res"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.006_bib38","first-page":"1593","article-title":"The combination of tacrolimus and entecavir improves the remission of HBV-associated glomerulonephritis without enhancing viral replication","volume":"8","author":"Wang","year":"2016","journal-title":"Am J Transl Res"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.006_bib39","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000185802","article-title":"The therapeutic dilemma of the usage of corticosteroid in patients with membranous nephropathy and persistent hepatitis B\u00a0virus surface antigenaemia","volume":"54","author":"Lai","year":"1990","journal-title":"Nephron"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.006_bib40","first-page":"161","article-title":"Transformation of hepatitis B virus-related membranous glomerulonephritis to crescentic form","volume":"54","author":"Taskapan","year":"2000","journal-title":"Clin Nephrol"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.006_bib41","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/BF00822033","article-title":"Replication of hepatitis B virus with corticosteroid therapy in hepatitis B virus related membranous nephropathy","volume":"414","author":"Lai","year":"1989","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.006_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.006_bib43","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.berh.2013.01.004","article-title":"Infections in vasculitis","volume":"27","author":"Guillevin","year":"2013","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.rdc.2018.06.006_bib44","first-page":"S40","article-title":"Clinical features and the natural course of hepatitis B virus-related glomerulopathy in adults","volume":"35","author":"Lai","year":"1991","journal-title":"Kidney Int Suppl"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.006_bib45","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1423-0410.1970.tb01550.x","article-title":"Hepatitis associated antigen and periarteritis nodosa (PAN)","volume":"19","author":"Trepo","year":"1970","journal-title":"Vox Sang"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.006_bib46","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/0002-9343(80)90170-9","article-title":"Hepatitis B antigen-associated periarteritis nodosa in patients undergoing long-term hemodialysis","volume":"68","author":"Drueke","year":"1980","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.rdc.2018.06.006_bib47","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1191\/096120398678920055","article-title":"Polyarteritis nodosa, microscopic polyangiitis and Churg-Strauss syndrome","volume":"7","author":"Lhote","year":"1998","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.rdc.2018.06.006_bib48","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1053\/j.tvir.2014.11.005","article-title":"Polyarteritis nodosa","volume":"17","author":"Howard","year":"2014","journal-title":"Tech Vasc Interv Radiol"},{"key":"10.1016\/j.rdc.2018.06.006_bib49","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jaut.2014.01.029","article-title":"Diagnosis and classification of polyarteritis nodosa","volume":"48-49","author":"Hernandez-Rodriguez","year":"2014","journal-title":"J\u00a0Autoimmun"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.006_bib50","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/art.27240","article-title":"Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database","volume":"62","author":"Pagnoux","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.006_bib51","first-page":"63","article-title":"Polyarteritis nodosa-induced pancreaticoduodenal artery aneurysmal rupture","volume":"24","author":"Levin","year":"2015","journal-title":"Int J Angiol"},{"issue":"3\u20135","key":"10.1016\/j.rdc.2018.06.006_bib52","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF00271875","article-title":"Immunology of hepatitis B virus infections","volume":"9","author":"Heermann","year":"1989","journal-title":"Rheumatol Int"},{"issue":"4","key":"10.1016\/j.rdc.2018.06.006_bib53","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0049-0172(89)90043-7","article-title":"The rheumatic manifestations of infection with the human immunodeficiency virus","volume":"18","author":"Calabrese","year":"1989","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.rdc.2018.06.006_bib54","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1080\/08916930802613210","article-title":"The infectious etiology of vasculitis","volume":"42","author":"Lidar","year":"2009","journal-title":"Autoimmunity"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.006_bib55","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1006\/jaut.2000.0502","article-title":"Polyarteritis nodosa and extrahepatic manifestations of HBV infection: the case against autoimmune intervention in pathogenesis","volume":"16","author":"Trepo","year":"2001","journal-title":"J\u00a0Autoimmun"},{"issue":"5","key":"10.1016\/j.rdc.2018.06.006_bib56","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/00005792-199509000-00002","article-title":"Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients","volume":"74","author":"Guillevin","year":"1995","journal-title":"Medicine"},{"issue":"6","key":"10.1016\/j.rdc.2018.06.006_bib57","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.autrev.2016.02.015","article-title":"Polyarteritis nodosa: a contemporary overview","volume":"15","author":"De Virgilio","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.rdc.2018.06.006_bib58","first-page":"1345","article-title":"Antineutrophil cytoplasm antibodies in systemic polyarteritis nodosa with and without hepatitis B virus infection and Churg-Strauss syndrome\u201362 patients","volume":"20","author":"Guillevin","year":"1993","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.006_bib59","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJM198401053100110","article-title":"Hepatitis B and immune-complex disease","volume":"310","author":"Shusterman","year":"1984","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.006_bib60","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/BOR.0b013e328011cb6f","article-title":"The challenge of managing patients with polyarteritis nodosa","volume":"19","author":"Segelmark","year":"2007","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2018.06.006_bib61","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/01.md.0000180792.80212.5e","article-title":"Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients","volume":"84","author":"Guillevin","year":"2005","journal-title":"Medicine"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.006_bib62","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2332\/allergolint.R-07-144","article-title":"Therapeutic strategies for systemic necrotizing vasculitides","volume":"56","author":"Guillevin","year":"2007","journal-title":"Allergol Int"},{"issue":"4","key":"10.1016\/j.rdc.2018.06.006_bib63","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jbspin.2012.10.023","article-title":"Therapeutic immunomodulation in systemic vasculitis: taking stock","volume":"80","author":"Puechal","year":"2013","journal-title":"Joint Bone Spine"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.006_bib64","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/ard.2008.088096","article-title":"EULAR recommendations for the management of primary small and medium vessel vasculitis","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"10.1016\/j.rdc.2018.06.006_bib65","first-page":"63","article-title":"Polyarteritis nodosa related to hepatitis B virus. A retrospective study of 66 patients","volume":"143","author":"Guillevin","year":"1992","journal-title":"Ann Med Interne (Paris)"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.006_bib66","first-page":"289","article-title":"Treatment of polyarteritis nodosa related to hepatitis B virus with short term steroid therapy associated with antiviral agents and plasma exchanges. A prospective trial in 33 patients","volume":"20","author":"Guillevin","year":"1993","journal-title":"J\u00a0Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.006_bib67","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/art.20401","article-title":"Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa","volume":"51","author":"Guillevin","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.006_bib68","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000355778","article-title":"HBV-associated cryoglobulinemic vasculitis: remission after antiviral therapy with entecavir","volume":"39","author":"Vigano","year":"2014","journal-title":"Kidney Blood Press Res"},{"issue":"12","key":"10.1016\/j.rdc.2018.06.006_bib69","doi-asserted-by":"crossref","first-page":"912","DOI":"10.7326\/0003-4819-149-12-200812160-00019","article-title":"Entecavir to treat hepatitis B-associated cryoglobulinemic vasculitis","volume":"149","author":"Enomoto","year":"2008","journal-title":"Ann Intern Med"},{"issue":"2 Suppl 41","key":"10.1016\/j.rdc.2018.06.006_bib70","first-page":"S71","article-title":"Vasculitides secondary to infections","volume":"24","author":"Pagnoux","year":"2006","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.006_bib71","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.berh.2015.05.007","article-title":"Vasculitis related to viral and other microbial agents","volume":"29","author":"Teng","year":"2015","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.rdc.2018.06.006_bib72","unstructured":"Division of Viral Hepatitis and National Center for HIV\/AIDS VH S, and TB Prevention., Surveillance for Viral Hepatitis - United States, 2015. 2015. Available at: https:\/\/www.cdc.gov\/hepatitis\/statistics\/2015surveillance\/commentary.htm. Accessed June 19, 2017."},{"issue":"6","key":"10.1016\/j.rdc.2018.06.006_bib73","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.4049\/jimmunol.169.6.3447","article-title":"Impaired effector function of hepatitis C virus-specific CD8+ T\u00a0cells in chronic hepatitis C virus infection","volume":"169","author":"Wedemeyer","year":"2002","journal-title":"J\u00a0Immunol"},{"issue":"9055","key":"10.1016\/j.rdc.2018.06.006_bib74","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","article-title":"Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups","volume":"349","author":"Poynard","year":"1997","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.006_bib75","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/jcp.55.1.4","article-title":"Cryoglobulins","volume":"55","author":"Ferri","year":"2002","journal-title":"J\u00a0Clin Pathol"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.006_bib76","first-page":"79","article-title":"Mixed cryoglobulinemia cross-reactive idiotypes: implications for the relationship of MC to rheumatic and lymphoproliferative diseases.","volume":"28","author":"Gorevic","year":"1991","journal-title":"Seminars in hematology"},{"issue":"7","key":"10.1016\/j.rdc.2018.06.006_bib77","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1046\/j.1365-2362.2001.00824.x","article-title":"The cryoglobulins: an overview","volume":"31","author":"Dammacco","year":"2001","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.rdc.2018.06.006_bib78","first-page":"156","article-title":"Hyperproteinemia associated with multiple myeloma: with report of case in which an extraordinary hyperproteinemia was associated with thrombosis of the retinal veins and symptoms suggesting Raynaud's disease","volume":"52","author":"Wintrobe","year":"1933","journal-title":"Bull Johns Hopkins Hosp"},{"key":"10.1016\/j.rdc.2018.06.006_bib79","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/0002-9343(62)90191-2","article-title":"Cryoglobulinemia based on interaction between a gamma macroglobulin and 7S gamma globulin","volume":"32","author":"Lospalluto","year":"1962","journal-title":"Am J Med"},{"key":"10.1016\/j.rdc.2018.06.006_bib80","volume":"vol. 20","author":"Pascual","year":"1996"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.006_bib81","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1046\/j.1365-2893.2000.00204.x","article-title":"Prevalence and risk factors for the presence of serum cryoglobulins in patients with chronic hepatitis C","volume":"7","author":"Cicardi","year":"2000","journal-title":"J\u00a0Viral Hepat"},{"issue":"4","key":"10.1016\/j.rdc.2018.06.006_bib82","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00005792-200107000-00004","article-title":"Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center","volume":"80","author":"Trejo","year":"2001","journal-title":"Medicine"},{"issue":"24","key":"10.1016\/j.rdc.2018.06.006_bib83","doi-asserted-by":"crossref","first-page":"7544","DOI":"10.3748\/wjg.v20.i24.7544","article-title":"Hepatitis C virus associated glomerulopathies","volume":"20","author":"Ozkok","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.006_bib84","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1046\/j.1523-1755.1998.00028.x","article-title":"Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis","volume":"54","author":"D\u2019Amico","year":"1998","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.006_bib85","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1365-2893.2000.00194.x","article-title":"Hepatitis C virus RNA in kidney biopsies from infected patients with renal diseases","volume":"7","author":"Rodriguez-Inigo","year":"2000","journal-title":"J\u00a0viral Hepat"},{"issue":"suppl 8","key":"10.1016\/j.rdc.2018.06.006_bib86","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/ndt\/15.suppl_8.28","article-title":"Glomerular disease associated with hepatitis C virus infection in native kidneys","volume":"15","author":"Pouteil-Noble","year":"2000","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.006_bib87","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/ki.1988.152","article-title":"Identification of glomerular immune deposits in cryoglobulinemia glomerulonephritis","volume":"34","author":"Sinico","year":"1988","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.rdc.2018.06.006_bib88","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/ki.1989.84","article-title":"Renal involvement in essential mixed cryoglobulinemia","volume":"35","author":"D'Amico","year":"1989","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.rdc.2018.06.006_bib89","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.semarthrit.2003.10.001","article-title":"Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients","volume":"33","author":"Ferri","year":"2004","journal-title":"Seminars in arthritis and rheumatism"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.006_bib90","first-page":"141","article-title":"Hepatitis C virus associated membranous glomerulonephritis","volume":"44","author":"Stehman-Breen","year":"1995","journal-title":"Clin Nephrol"},{"issue":"6","key":"10.1016\/j.rdc.2018.06.006_bib91","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1038\/ki.1994.471","article-title":"Hepatitis C virus-associated glomerulonephritis. Effect of \u03b1-interferon therapy","volume":"46","author":"Johnson","year":"1994","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.006_bib92","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0272-6386(97)90020-2","article-title":"Fibrillary glomerulonephritis associated with hepatitis C viral infection","volume":"29","author":"Coroneos","year":"1997","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"10.1016\/j.rdc.2018.06.006_bib93","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1681\/ASN.V9122244","article-title":"Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy","volume":"9","author":"Markowitz","year":"1998","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.rdc.2018.06.006_bib94","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1046\/j.1523-1755.2003.00853.x","article-title":"Fibrillary and immunotactoid glomerulonephritis: distinct entities with different clinical and pathologic features","volume":"63","author":"Rosenstock","year":"2003","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.006_bib95","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/08860229309054952","article-title":"Immunotactoid glomerulopathy (ITGP): a not fully defined clinicopathologic entity","volume":"15","author":"Monga","year":"1993","journal-title":"Ren Fail"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.006_bib96","first-page":"279","article-title":"Fibrillary renal deposits and nephritis","volume":"113","author":"Duffy","year":"1983","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.006_bib97","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/ki.1987.66","article-title":"Fibrillary glomerulonephritis: an entity with unusual immunofluorescence features","volume":"31","author":"Alpers","year":"1987","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.rdc.2018.06.006_bib98","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/ki.1992.433","article-title":"Clinical and pathologic features of fibrillary glomerulonephritis","volume":"42","author":"Iskandar","year":"1992","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.rdc.2018.06.006_bib99","first-page":"714","article-title":"Removal systems of immunoglobulin A and immunoglobulin A containing complexes in IgA nephropathy and cirrhosis patients. The role of asialoglycoprotein receptors","volume":"69","author":"Roccatello","year":"1993","journal-title":"Lab Invest"},{"issue":"7","key":"10.1016\/j.rdc.2018.06.006_bib100","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1056\/NEJM199302183280703","article-title":"Membranoproliferative glomerulonephritis associated with hepatitis C virus infection","volume":"328","author":"Johnson","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.rdc.2018.06.006_bib101","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1056\/NEJM199403173301104","article-title":"Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus","volume":"330","author":"Misiani","year":"1994","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.rdc.2018.06.006_bib102","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood.V90.10.3865","article-title":"Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection","volume":"90","author":"Casato","year":"1997","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.rdc.2018.06.006_bib103","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/blood.V81.5.1132.1132","article-title":"Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial","volume":"81","author":"Ferri","year":"1993","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.rdc.2018.06.006_bib104","first-page":"2466","article-title":"Longterm efficacy of interferon-alpha for extrahepatic disease associated with hepatitis C virus infection","volume":"28","author":"Naarendorp","year":"2001","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2018.06.006_bib105","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jhep.2004.10.031","article-title":"Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study","volume":"42","author":"Mazzaro","year":"2005","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.rdc.2018.06.006_bib106","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-\u03b12a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.rdc.2018.06.006_bib107","first-page":"2078","article-title":"Treatment of hepatitis C virus-related systemic vasculitis","volume":"32","author":"Cacoub","year":"2005","journal-title":"J\u00a0Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.006_bib108","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood-2009-10-245878","article-title":"Pegylated interferon-\u03b1, ribavirin, and rituximab combined therapy of hepatitis C virus\u2013related mixed cryoglobulinemia: a long-term study","volume":"116","author":"Dammacco","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.rdc.2018.06.006_bib109","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1002\/art.10699","article-title":"Interferon-\u03b1 and ribavirin treatment in patients with hepatitis C virus\u2013related systemic vasculitis","volume":"46","author":"Cacoub","year":"2002","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.006_bib110","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/art.20958","article-title":"PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus\u2013related systemic vasculitis","volume":"52","author":"Cacoub","year":"2005","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"10.1016\/j.rdc.2018.06.006_bib111","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1002\/art.22168","article-title":"Antiviral therapy for hepatitis C virus\u2013associated mixed cryoglobulinemia vasculitis: a long-term followup study","volume":"54","author":"Saadoun","year":"2006","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2018.06.006_bib112","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1053\/j.ajkd.2003.11.020","article-title":"Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN","volume":"43","author":"Alric","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"10.1016\/j.rdc.2018.06.006_bib113","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/ndt\/gfg209","article-title":"Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency","volume":"18","author":"Bruchfeld","year":"2003","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.1016\/j.rdc.2018.06.006_bib114","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2002-10-3162","article-title":"Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon \u03b1 with an anti-CD20","volume":"101","author":"Sansonno","year":"2003","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.rdc.2018.06.006_bib115","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1080\/1042819031000119235","article-title":"Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases","volume":"44","author":"Zaja","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.rdc.2018.06.006_bib116","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1093\/ndt\/gfh469","article-title":"Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis","volume":"19","author":"Roccatello","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"10.1016\/j.rdc.2018.06.006_bib117","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/rheumatology\/kel004","article-title":"Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids","volume":"45","author":"Quartuccio","year":"2006","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.006_bib118","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jhep.2014.08.015","article-title":"PegIFN\u03b1\/ribavirin\/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis","volume":"62","author":"Saadoun","year":"2015","journal-title":"J\u00a0Hepatol"},{"issue":"10","key":"10.1016\/j.rdc.2018.06.006_bib119","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1136\/ard.2007.081653","article-title":"Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis","volume":"67","author":"Saadoun","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.006_bib120","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1136\/ard.2006.065565","article-title":"Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand?","volume":"67","author":"Cacoub","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.006_bib121","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/blood-2009-10-248518","article-title":"Rituximab plus Peg-interferon-\u03b1\/ribavirin compared with Peg-interferon-\u03b1\/ribavirin in hepatitis C\u2013related mixed cryoglobulinemia","volume":"116","author":"Saadoun","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.006_bib122","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/art.34331","article-title":"A\u00a0randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis","volume":"64","author":"De Vita","year":"2012","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.006_bib123","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/art.34322","article-title":"A\u00a0randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus\u2013associated cryoglobulinemic vasculitis","volume":"64","author":"Sneller","year":"2012","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2018.06.006_bib124","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1053\/j.ajkd.2008.08.005","article-title":"KDOQI US commentary on the KDIGO clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in CKD","volume":"52","author":"Gordon","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.rdc.2018.06.006_bib125","unstructured":"AASLD-IDSA. HCV guidance: recommendations for testing, managing, and treating hepatitis C. 2017. Available at: http:\/\/www.hcvguidelines.org. Accessed July 2, 2017."},{"issue":"7","key":"10.1016\/j.rdc.2018.06.006_bib126","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1053\/j.gastro.2016.02.078","article-title":"Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease","volume":"150","author":"Pockros","year":"2016","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.rdc.2018.06.006_bib127","first-page":"1125A","article-title":"EXPEDITION-IV: safety and efficacy of GLE\/PIB in adults with renal impairment and Chronic Hepatitis C Virus Genotype 1 \u2013 6 Infection","volume":"64","author":"Gane","year":"2016","journal-title":"Hepatology"},{"issue":"10003","key":"10.1016\/j.rdc.2018.06.006_bib128","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.rdc.2018.06.006_bib129","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/liv.13102","article-title":"Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function","volume":"36","author":"Saxena","year":"2016","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.006_bib130","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jhep.2015.06.004","article-title":"Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease","volume":"63","author":"Kalyan Ram","year":"2015","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.rdc.2018.06.006_bib131","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/liv.13025","article-title":"Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR<\u00a030\u00a0ml\/min","volume":"36","author":"Nazario","year":"2016","journal-title":"Liver Int"},{"issue":"7","key":"10.1016\/j.rdc.2018.06.006_bib132","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/liv.13336","article-title":"Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis","volume":"37","author":"Li","year":"2017","journal-title":"Liver Int"},{"issue":"27","key":"10.1016\/j.rdc.2018.06.006_bib133","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.006_bib134","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1053\/j.gastro.2017.03.006","article-title":"Efficacy and safety of sofosbuvir plus daclatasvir for treatment of HCV-associated cryoglobulinemia vasculitis","volume":"153","author":"Saadoun","year":"2017","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.rdc.2018.06.006_bib135","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/ajg.2017.49","article-title":"Efficacy and safety of direct acting antivirals for the treatment of mixed cryoglobulinemia","volume":"112","author":"Emery","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.rdc.2018.06.006_bib136","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cgh.2016.09.158","article-title":"Virologic, clinical, and immune response outcomes of patients with hepatitis C virus\u2013associated cryoglobulinemia treated with direct-acting antivirals","volume":"15","author":"Bonacci","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.006_bib137","doi-asserted-by":"crossref","first-page":"S505","DOI":"10.1016\/S0168-8278(17)31410-1","article-title":"FRI-216-Sofosbuvir\/Ribavirin treatment in patients with genotype 2, Hepatitis C Virus infection and symptomatic mixed cryoglobulinemia: an interim analysis on safety, efficacy and impact on quality of life","volume":"66","author":"Cerretelli","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.rdc.2018.06.006_bib138","doi-asserted-by":"crossref","first-page":"772","DOI":"10.2174\/1389450117666160208145432","article-title":"Virological and clinical response to interferon-free regimens in patients with HCV-related mixed cryoglobulinemia: preliminary results of a prospective pilot study","volume":"18","author":"Gragnani","year":"2017","journal-title":"Curr Drug Targets"},{"issue":"10","key":"10.1016\/j.rdc.2018.06.006_bib139","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1136\/annrheumdis-2015-208339","article-title":"Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study","volume":"75","author":"Saadoun","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2018.06.006_bib140","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1053\/j.gastro.2017.02.037","article-title":"Direct-acting antiviral therapy restores immune tolerance to patients with hepatitis c virus\u2013induced cryoglobulinemia vasculitis","volume":"152","author":"Comarmond","year":"2017","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.006_bib141","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/j.dld.2017.01.068","article-title":"Direct acting antiviral (DAA) therapy of HCV, effects on the cryoglobulinemic vasculitis: a multi center open label study","volume":"49","author":"Mauro","year":"2017","journal-title":"Dig Liver Dis"},{"issue":"5","key":"10.1016\/j.rdc.2018.06.006_bib142","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/hep.28753","article-title":"Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia","volume":"64","author":"Gragnani","year":"2016","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.006_bib143","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/hep.28297","article-title":"Treatment of hepatitis C virus\u2013associated mixed cryoglobulinemia with direct-acting antiviral agents","volume":"63","author":"Sise","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.006_bib144","doi-asserted-by":"crossref","first-page":"S528","DOI":"10.1016\/S0168-8278(17)31459-9","article-title":"FRI-265-Benefit of direct-acting antiviral therapy in hepatitis C virus (HCV) monoinfected and HIV-HCV coinfected patients with mixed cryoglobulinemia","volume":"66","author":"Diakite","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"11","key":"10.1016\/j.rdc.2018.06.006_bib145","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1093\/rheumatology\/kew268","article-title":"Persistent mixed cryoglobulinaemia vasculitis despite hepatitis C virus eradication after interferon-free antiviral therapy","volume":"55","author":"Sollima","year":"2016","journal-title":"Rheumatology"},{"issue":"12","key":"10.1016\/j.rdc.2018.06.006_bib146","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1111\/liv.13465","article-title":"Effectiveness and cost of hepatitis C virus cryoglobulinemia vasculitis treatment: from interferon-based to direct acting antivirals era","volume":"37","author":"Cacoub","year":"2017","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.rdc.2018.06.006_bib147","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/00325481.2015.1021660","article-title":"Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: a case series","volume":"127","author":"Cornella","year":"2015","journal-title":"Postgrad Med"},{"issue":"9","key":"10.1016\/j.rdc.2018.06.006_bib148","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.dld.2014.05.017","article-title":"Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study","volume":"46","author":"Gragnani","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.rdc.2018.06.006_bib149","unstructured":"KDIGO. KDIGO 2017 clinical practice guideline on the prevention, diagnosis, evaluation and treatment of hepatitis C in CKD. 2017. Accessed February 8, 2017. Available at: https:\/\/kdigo.org\/clinical_practice_guidelines\/Hep%20C\/KDIGO%202017%20Hep%20C%20GL%20Public%20Review%20Draft%20FINAL.pdf"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.006_bib150","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s004670000467","article-title":"Interferon treatment on glomerulonephritis associated with hepatitis C virus","volume":"15","author":"Matsumoto","year":"2000","journal-title":"Pediatr Nephrol"},{"issue":"22","key":"10.1016\/j.rdc.2018.06.006_bib151","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.2169\/internalmedicine.49.4365","article-title":"Successful interferon-\u03b1 treatment in a patient with IgA nephropathy associated with hepatitis C virus infection","volume":"49","author":"Ji","year":"2010","journal-title":"Intern Med"},{"issue":"8","key":"10.1016\/j.rdc.2018.06.006_bib152","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1016\/S2352-3018(16)30087-X","article-title":"Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015","volume":"3","year":"2016","journal-title":"Lancet HIV"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.006_bib153","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/path.4449","article-title":"HIV and the spectrum of human disease","volume":"235","author":"Lucas","year":"2015","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.rdc.2018.06.006_bib154","unstructured":"WHO. Number of deaths due to HIV. 2018. Available at: http:\/\/www.who.int\/gho\/hiv\/epidemic_status\/deaths\/en\/. Accessed April 18, 2018."},{"issue":"13","key":"10.1016\/j.rdc.2018.06.006_bib155","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators","volume":"338","author":"Palella","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.rdc.2018.06.006_bib156","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1001\/jamainternmed.2013.3728","article-title":"HIV infection and the risk of acute myocardial infarction","volume":"173","author":"Freiberg","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"8","key":"10.1016\/j.rdc.2018.06.006_bib157","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/archinternmed.2011.151","article-title":"Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease","volume":"171","author":"Butt","year":"2011","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.006_bib158","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.hivar.2014.09.002","article-title":"Metabolic syndrome in HIV-positive patients","volume":"14","author":"Drelichowska","year":"2015","journal-title":"HIV & AIDS Review"},{"issue":"11","key":"10.1016\/j.rdc.2018.06.006_bib159","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1086\/593099","article-title":"Kidney disease in patients with HIV infection and AIDS","volume":"47","author":"Winston","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.rdc.2018.06.006_bib160","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/QAD.0000000000000653","article-title":"The burden of dialysis-requiring acute kidney injury among hospitalized adults with HIV infection: a nationwide inpatient sample analysis","volume":"29","author":"Nadkarni","year":"2015","journal-title":"AIDS"},{"issue":"8","key":"10.1016\/j.rdc.2018.06.006_bib161","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/QAD.0000000000000628","article-title":"Nonalbumin proteinuria predominates in biopsy-proven tenofovir nephrotoxicity","volume":"29","author":"Sise","year":"2015","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.006_bib162","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/nrneph.2015.9","article-title":"HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment","volume":"11","author":"Rosenberg","year":"2015","journal-title":"Nat Rev Nephrol"},{"issue":"11","key":"10.1016\/j.rdc.2018.06.006_bib163","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM198403153101101","article-title":"Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome","volume":"310","author":"Rao","year":"1984","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.rdc.2018.06.006_bib164","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMcpc1616395","article-title":"Case 12-2017-A 34-year-old man with nephropathy","volume":"376","author":"Sise","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.rdc.2018.06.006_bib165","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1093\/ndt\/gfv207","article-title":"Trends in the outcomes of end-stage renal disease secondary to human immunodeficiency virus-associated nephropathy","volume":"30","author":"Razzak Chaudhary","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.006_bib166","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/ndt\/gfr376","article-title":"Presentation of HIV-associated nephropathy and outcome in HAART-treated patients","volume":"27","author":"Bige","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.006_bib167","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1172\/JCI119525","article-title":"Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression","volume":"100","author":"Bruggeman","year":"1997","journal-title":"J\u00a0Clin Invest"},{"issue":"11","key":"10.1016\/j.rdc.2018.06.006_bib168","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1681\/ASN.2011040388","article-title":"APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy","volume":"22","author":"Kopp","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.rdc.2018.06.006_bib169","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1681\/ASN.2011040434","article-title":"APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy","volume":"22","author":"Papeta","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.006_bib170","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00002030-200402200-00022","article-title":"Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study","volume":"18","author":"Lucas","year":"2004","journal-title":"AIDS"},{"issue":"8","key":"10.1016\/j.rdc.2018.06.006_bib171","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1681\/ASN.2005040340","article-title":"Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease","volume":"16","author":"Schwartz","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.rdc.2018.06.006_bib172","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1093\/ndt\/gfr676","article-title":"HIV-associated kidney glomerular diseases: changes with time and HAART","volume":"27","author":"Lescure","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"10.1016\/j.rdc.2018.06.006_bib173","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1093\/cid\/ciu617","article-title":"Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America","volume":"59","author":"Lucas","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.rdc.2018.06.006_bib174","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1093\/ndt\/gfl337","article-title":"Antiretroviral therapy in the treatment of HIV-associated nephropathy","volume":"21","author":"Atta","year":"2006","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"10.1016\/j.rdc.2018.06.006_bib175","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1681\/ASN.V871140","article-title":"Effect of angiotensin-converting enzyme inhibition in HIV-associated nephropathy","volume":"8","author":"Burns","year":"1997","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.rdc.2018.06.006_bib176","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1086\/529385","article-title":"Predictors of renal outcome in HIV-associated nephropathy","volume":"46","author":"Post","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"21","key":"10.1016\/j.rdc.2018.06.006_bib177","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMoa1001197","article-title":"Outcomes of kidney transplantation in HIV-infected recipients","volume":"363","author":"Stock","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.rdc.2018.06.006_bib178","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.2215\/CJN.10991012","article-title":"Comparison of risk factors and outcomes in HIV immune complex kidney disease and HIV-associated nephropathy","volume":"8","author":"Foy","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.006_bib179","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.1523-1755.2004.00865.x","article-title":"The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection","volume":"66","author":"Szczech","year":"2004","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.rdc.2018.06.006_bib180","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00126334-200403010-00007","article-title":"Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases","volume":"35","author":"Peyriere","year":"2004","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"1","key":"10.1016\/j.rdc.2018.06.006_bib181","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/135965350601100108","article-title":"Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy","volume":"11","author":"Cote","year":"2006","journal-title":"Antivir Ther"},{"issue":"11","key":"10.1016\/j.rdc.2018.06.006_bib182","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/ki.2010.318","article-title":"Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities","volume":"78","author":"Herlitz","year":"2010","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.rdc.2018.06.006_bib183","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/QAI.0000000000000908","article-title":"Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label phase 3 study","volume":"71","author":"Pozniak","year":"2016","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"10","key":"10.1016\/j.rdc.2018.06.006_bib184","doi-asserted-by":"crossref","first-page":"e77268","DOI":"10.1371\/journal.pone.0077268","article-title":"Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients","volume":"8","author":"Nishijima","year":"2013","journal-title":"PLoS One"},{"issue":"17","key":"10.1016\/j.rdc.2018.06.006_bib185","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1097\/QAD.0b013e3282f17503","article-title":"Atazanavir crystal nephropathy","volume":"21","author":"Izzedine","year":"2007","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.rdc.2018.06.006_bib186","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/ckj\/sfu008","article-title":"HIV medication-based urolithiasis","volume":"7","author":"Izzedine","year":"2014","journal-title":"Clin Kidney J"},{"issue":"Suppl 1","key":"10.1016\/j.rdc.2018.06.006_bib187","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/S0168-8278(03)00155-7","article-title":"Results of lamivudine trials in Asia","volume":"39","author":"Liaw","year":"2003","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.rdc.2018.06.006_bib188","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1272\/jnms.80.387","article-title":"Seroconversion of hepatitis B envelope antigen by entecavir in a child with hepatitis B virus-related membranous nephropathy","volume":"80","author":"Igarashi","year":"2013","journal-title":"J\u00a0Nippon Med Sch"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X18300590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X18300590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:16:50Z","timestamp":1760181410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X18300590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":188,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0889857X18300590"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2018.06.006","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoimmune Kidney Diseases Associated with Chronic Viral Infections","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2018.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}